GENITOURINARY CANCERS

ARV-110, a PROTAC^® protein degrader, has received a fast track designation from the FDA for the treatment of patients with metastatic castration-resistant prostate cancer who have disease progression following ≥2 systemic therapies.

Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.

Case Based Peer Perspectives: Metastatic Castration-Resistant Prostate Cancer

Updated NCCN guidelines in prostate cancer recommend integration of tumor genetic testing into clinical practice for patients with advanced prostate cancer. For patients with regional or metastatic disease, the guidelines recommend testing for homologous recombination gene mutations and for microsatellite instability or mismatch repair deficiency, according to Emmanuel S. Antonarakis, MBBCh.

Metastatic Hormone-Sensitive Prostate Cancer Progression to CRPC

The combination of avelumab (Bavencio) and axitinib (Inlyta) has been approved by the FDA for the frontline treatment of patients with advanced renal cell carcinoma, based on findings from the phase III JAVELIN Renal 101 trial.

Elizabeth Kessler, MD, explained to a group of physicians in a recent&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation the treatment considerations and decisions she makes when seeing a patient with prostate cancer in the clinic.

In a preliminary analysis of a phase II trial, the radiolabeled small molecule, ¹⁷⁷LuPSMA-617, demonstrated a biochemical progression-free survival of 4 months in a cohort of 64 men with metastatic castrate-resistant prostate cancer.

A phase III clinical trial evaluating&nbsp;cabozantinib (Cabometyx) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with previously untreated advanced renal cell carcinoma has been initiated, according to Exelixis, the developer of cabozantinib.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;April 2019, including several new approvals, a priority review, breakthrough designation, and more.

Apalutamide has been submitted for FDA approval for the treatment of patients with metastatic castration-sensitive prostate cancer.

A new drug application seeking the approval of darolutamide as a treatment for patients with nonmetastatic castration-resistant prostate cancer has been granted a priority review designation by the FDA.